These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 15811373)
1. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. Chen Y; Delmas J; Sirot J; Shoichet B; Bonnet R J Mol Biol; 2005 Apr; 348(2):349-62. PubMed ID: 15811373 [TBL] [Abstract][Full Text] [Related]
2. Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. Delmas J; Chen Y; Prati F; Robin F; Shoichet BK; Bonnet R J Mol Biol; 2008 Jan; 375(1):192-201. PubMed ID: 17999931 [TBL] [Abstract][Full Text] [Related]
3. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160 [TBL] [Abstract][Full Text] [Related]
4. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. Wang X; Minasov G; Shoichet BK Proteins; 2002 Apr; 47(1):86-96. PubMed ID: 11870868 [TBL] [Abstract][Full Text] [Related]
5. An engineered disulfide bond between residues 69 and 238 in extended-spectrum beta-lactamase Toho-1 reduces its activity toward third-generation cephalosporins. Shimizu-Ibuka A; Matsuzawa H; Sakai H Biochemistry; 2004 Dec; 43(50):15737-45. PubMed ID: 15595829 [TBL] [Abstract][Full Text] [Related]
6. The spread of CTX-M-type extended-spectrum beta-lactamases. Rossolini GM; D'Andrea MM; Mugnaioli C Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():33-41. PubMed ID: 18154526 [TBL] [Abstract][Full Text] [Related]
7. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. Wang X; Minasov G; Shoichet BK J Mol Biol; 2002 Jun; 320(1):85-95. PubMed ID: 12079336 [TBL] [Abstract][Full Text] [Related]
8. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. Stürenburg E; Kühn A; Mack D; Laufs R J Antimicrob Chemother; 2004 Aug; 54(2):406-9. PubMed ID: 15201232 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution. Ibuka A; Taguchi A; Ishiguro M; Fushinobu S; Ishii Y; Kamitori S; Okuyama K; Yamaguchi K; Konno M; Matsuzawa H J Mol Biol; 1999 Feb; 285(5):2079-87. PubMed ID: 9925786 [TBL] [Abstract][Full Text] [Related]
10. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases. Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307 [TBL] [Abstract][Full Text] [Related]
11. Structural insights into substrate recognition and product expulsion in CTX-M enzymes. Delmas J; Leyssene D; Dubois D; Birck C; Vazeille E; Robin F; Bonnet R J Mol Biol; 2010 Jul; 400(1):108-20. PubMed ID: 20452359 [TBL] [Abstract][Full Text] [Related]
12. High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal. Machado E; Coque TM; Cantón R; Novais A; Sousa JC; Baquero F; Peixe L; J Antimicrob Chemother; 2007 Dec; 60(6):1370-4. PubMed ID: 17913717 [TBL] [Abstract][Full Text] [Related]
13. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases. Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096 [TBL] [Abstract][Full Text] [Related]
14. Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9. Delmas J; Robin F; Carvalho F; Mongaret C; Bonnet R Antimicrob Agents Chemother; 2006 Feb; 50(2):731-8. PubMed ID: 16436733 [TBL] [Abstract][Full Text] [Related]
16. Predictive analysis of ceftazidime hydrolysis in CTX-M-type beta-lactamase family members with a mutational substitution at position 167. Kimura S; Ishii Y; Tateda K; Yamaguchi K Int J Antimicrob Agents; 2007 Mar; 29(3):326-31. PubMed ID: 17258896 [TBL] [Abstract][Full Text] [Related]
17. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study]. Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074 [TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamases in North America, 1987-2006. Bush K Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():134-43. PubMed ID: 18154537 [TBL] [Abstract][Full Text] [Related]
19. Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Ibuka AS; Ishii Y; Galleni M; Ishiguro M; Yamaguchi K; Frère JM; Matsuzawa H; Sakai H Biochemistry; 2003 Sep; 42(36):10634-43. PubMed ID: 12962487 [TBL] [Abstract][Full Text] [Related]
20. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. Yu Y; Ji S; Chen Y; Zhou W; Wei Z; Li L; Ma Y J Infect; 2007 Jan; 54(1):53-7. PubMed ID: 16533535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]